Dr. Mascarenhas about imetelstat: A drug and an approach to be keeping an eye out on

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
Fishermangents
Site Admin
Posts: 531
Joined: Thu Dec 03, 2015 3:39 pm

Dr. Mascarenhas about imetelstat: A drug and an approach to be keeping an eye out on

Post by Fishermangents » Thu Apr 21, 2016 8:11 pm

Examining Two Approaches for Improving the Care of Myelofibrosis
CURE spoke with John O. Mascarenhas about advancements in the care of myelofibrosis.
BRIELLE URCIUOLI
PUBLISHED: APRIL 20, 2016

From the interview:
'There are a number of different novel therapeutic approaches that are being evaluated that are non-JAK 2 inhibitor therapies, like the telomerase inhibitor imetelstat, which is a Geron drug. Along with Janssen, they’re running a large, multi-center, randomized phase 2 study evaluating two different doses of the intravenous drug that targets telomerase. This is a novel approach that has a lot of attention, mainly because the Mayo Clinic ran a pilot study in approximately 33 patients with advanced myelofibrosis and had some very exciting responses in terms of complete responses: resolution of bone marrow, histopathologic abnormalities, regression of bone marrow fibrosis and even complete molecular responses in a handful of patients. This is not something we would normally see, particularly in a pilot study. It would suggest that there is really a signal of clinical activity. That will be evaluated in a more robust fashion in a multi-center randomized setting. And I think that’s a drug and an approach to be keeping an eye out on.'

Read the full interiew: http://www.curetoday.com/articles/exami ... lofibrosis

Post Reply